CAPA – The Coalition Against Patent Abuse

    • Who We Are
    • The Problem
    • The Solution
    • Case Studies
      • Evasive Maneuvers to Avoid Patent Challenges
      • No-Innovation Patenting
      • Product Hopping
      • Regulatory Gridlock by Citizen Petition
    • News and Resources
      • In the Media
      • For the Media
      • Blog
      • Resources
  • Who We Are
  • The Problem
  • The Solution
  • Case Studies
    • Evasive Maneuvers to Avoid Patent Challenges
    • No-Innovation Patenting
    • Product Hopping
    • Regulatory Gridlock by Citizen Petition
  • News and Resources
    • In the Media
    • For the Media
    • Blog
    • Resources
  • Learn More

AbbVie’s Humira: The poster child for how drug companies abuse the patent system to keep drug prices high. But only for Americans.

  Humira is a medicine that treats a number of conditions and is widely prescribed and used by millions of people around the world. It is the most profitable drug in history. Like many brand name drugs, it is also very expensive, but it is particularly expensive here in the U.S. In fact, in Europe […]

Continue Reading
Recent Posts
  • THE REFILL: Latest Dosage of Rx Patent Abuse
  • ICYMI: CAPA Warns Recent Federal Circuit Court Decision Could Erode Hatch-Waxman, Lead to Even Higher Drug Prices
  • In Case You Missed It: Washington Post Op-Ed Outlines How Patent Reforms Could Lower Drug Prices
  • THE REFILL: Latest Dosage of Rx Patent Abuse
  • Big Pharma Price Hikes Continue As Americans Grapple With Financial Hardships
Archives
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • February 2019
  • January 2019

Email Us: [email protected]

  • Privacy Policy
  • Terms of Use

©2019 Coalition Against Patent Abuse. All Rights Reserved.